[go: up one dir, main page]

GB202102105D0 - Prognostic method - Google Patents

Prognostic method

Info

Publication number
GB202102105D0
GB202102105D0 GBGB2102105.0A GB202102105A GB202102105D0 GB 202102105 D0 GB202102105 D0 GB 202102105D0 GB 202102105 A GB202102105 A GB 202102105A GB 202102105 D0 GB202102105 D0 GB 202102105D0
Authority
GB
United Kingdom
Prior art keywords
prognostic method
prognostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2102105.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NovaBiotics Ltd
Original Assignee
NovaBiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NovaBiotics Ltd filed Critical NovaBiotics Ltd
Priority to GBGB2102105.0A priority Critical patent/GB202102105D0/en
Publication of GB202102105D0 publication Critical patent/GB202102105D0/en
Priority to PCT/GB2022/050405 priority patent/WO2022172039A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GBGB2102105.0A 2021-02-15 2021-02-15 Prognostic method Ceased GB202102105D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2102105.0A GB202102105D0 (en) 2021-02-15 2021-02-15 Prognostic method
PCT/GB2022/050405 WO2022172039A1 (en) 2021-02-15 2022-02-15 Method for determining risk of viral infection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2102105.0A GB202102105D0 (en) 2021-02-15 2021-02-15 Prognostic method

Publications (1)

Publication Number Publication Date
GB202102105D0 true GB202102105D0 (en) 2021-03-31

Family

ID=75339040

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2102105.0A Ceased GB202102105D0 (en) 2021-02-15 2021-02-15 Prognostic method

Country Status (2)

Country Link
GB (1) GB202102105D0 (en)
WO (1) WO2022172039A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2411812B1 (en) * 2009-03-24 2013-10-02 AnaMar AB Metabolic profiles
GB201101667D0 (en) * 2011-01-31 2011-03-16 Imp Innovations Ltd Diagnostic method
US20200386766A1 (en) * 2016-12-22 2020-12-10 Metabolomycs, Inc. Metabolic signatures associated with diagnosis, disease progression, and immunological response to treatment of patients with covid-19

Also Published As

Publication number Publication date
WO2022172039A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
GB202014709D0 (en) Method
GB202010104D0 (en) Method
GB202004944D0 (en) Method
GB202007044D0 (en) Method
GB202015993D0 (en) Method
GB202014432D0 (en) Method
GB202010922D0 (en) Method
GB202100827D0 (en) Method
GB202018514D0 (en) Method
GB202006815D0 (en) Method
GB202004863D0 (en) Method
GB202017861D0 (en) Method
GB202016334D0 (en) Method
GB202011823D0 (en) Method
GB202102105D0 (en) Prognostic method
GB202018262D0 (en) Method
GB202010046D0 (en) Method
GB202009928D0 (en) Method
GB202006047D0 (en) Method
GB202005184D0 (en) Method
GB202004515D0 (en) Method
GB202003580D0 (en) Method
GB202100365D0 (en) Method
GB202020180D0 (en) Method
GB202020183D0 (en) Method

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)